Pulminiq Advisory Cmte. Splits On Survival Benefit In Lung Transplant
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA committee members differ on whether Chiron should be required to conduct another trial prior to approval to confirm the suggested survival benefit seen in a lung transplant trial of aerosolized cyclosporine. Chiron points to difficulty in conducting a second placebo-controlled trial.